BioSpace News Archive

The Hang Seng Composite Index offers a comprehensive Hong Kong market benchmark that covers about the top 95th percentile of the total market capitalization of companies listed on the Main Board of the Stock Exchange of Hong Kong (SEHK).

Hangzhou Sciwind Biosciences Co., Ltd., a clinical-stage, fast-growing biotech focusing on research and development of innovative biologics, announced that XW003, a potential candidate for the treatment of non-alcoholic steatohepatitis, has been approved by China NMPA for clinical trial.

Junshi grants AstraZeneca exclusive promotion rights of toripalimab in mainland China for the urothelial carcinoma indications and for all indications in non-core areas

Everest Medicines announced that the company has been selected as a constituent stock of the Hang Seng Composite Index, the Hang Seng Healthcare Index and the Hang Seng Hong Kong-Listed Biotech Index in accordance with the latest index series release by Hang Seng Indexed Company Limited, with effect from March 15, 2021.